RARE DISEASE
Linear IgA dermatosis
Linear IgA dermatosis
Linear IgA dermatosis
Drug discovery
1
drug
With orphan designation
Overview
Linear IgA dermatosis (LAD) is a rare autoimmune blistering disorder characterized by linear IgA deposition at the dermo-epidermal basement membrane. It manifests with tense blisters, annular plaques, and mucosal involvement (oral, ocular, or genital) in 70–80% of cases [1][6][10]. Diagnosis relies on direct immunofluorescence showing IgA linear deposition. While idiopathic in most cases, triggers include medications (vancomycin, NSAIDs), infections, and malignancies [1][6][11]. First-line treatment is dapsone or sulfonamides, with topical corticosteroids for mild cases [3][16]. Childhood-onset LAD typically resolves within 2–4 years, whereas adult forms are often chronic [10][16].
Burden
Childhood LAD: Self-limiting (median 3-year duration) with minimal scarring [6][10].
Adult LAD: Chronic course (30–40% remission rate) with risks of mucosal scarring (e.g., blindness, esophageal strictures) [1][6][10].
Associated comorbidities: lymphoproliferative disorders, ulcerative colitis, and reduced quality of life due to chronic pruritus and blistering [6][11][15].
Therapies
First-line: Dapsone (50–200 mg/day) or sulfonamides (sulfapyridine/sulfamethoxypyridazine) [1][3][16].
Adjunctive: Topical corticosteroids (clobetasol 0.05%) for localized disease; systemic corticosteroids for severe flares [3][16].
Refractory cases: IV immunoglobulin (IVIg), rituximab, colchicine, or mycophenolate mofetil [1][3][12].
Categories: rare skin diseases
Research Papers
151 drug discovery papers about Linear IgA dermatosis, with 2 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
151 drug discovery papers about Linear IgA dermatosis, with 2 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-08 | Rituximab for Refractory Adult Linear Iga Bullous Dermatosis: A Case Report
Linear IgA bullous dermatosis (LABD) is a rare autoimmune bullous disease characterized by linear IgA deposition along the basement membrane zone. While dapsone remains the cornerstone of treatment, a subset of adult patients develops severe, treatment-refractory disease requiring prolonged systemic corticosteroid therapy, and the role of rituximab in this setting remains poorly documented. We report the case of a 34-year-old woman with severe mucocutaneous LABD who failed to achieve disease control despite 18 months of treatment with dapsone, high-dose systemic corticosteroids, and doxycycline, resulting in persistent corticosteroid dependence and significant impairment in quality of life. Following confirmation of the diagnosis by repeat histopathology and direct immunofluorescence, rituximab was initiated using the pemphigus protocol (two 1-g infusions administered two weeks apart), followed by maintenance infusions every six months. A marked and sustained clinical improvement became evident from the second treatment cycle, allowing complete withdrawal of systemic corticosteroids and doxycycline, and at the latest follow-up the patient remained clinically stable on dapsone monotherapy, with only minimal residual cutaneous activity. This case highlights rituximab as a promising steroid-sparing rescue therapy for severe refractory adult LABD and contributes to the limited evidence supporting its use in this uncommon autoimmune bullous disease; further studies are needed to establish its optimal treatment regimen and long-term efficacy.
2026-06-16 | Management of Recurrent Linear IgA Dermatosis of Childhood in the Absence of Histopathology and Immunofluorescence: A Case Report from a Low-Resource Setting in South-Western Uganda.
Linear IgA Dermatosis of Childhood (LAD of childhood) is a rare autoimmune sub-epidermal blistering disorder classically confirmed by direct immunofluorescence demonstrating linear IgA deposition along the basement membrane zone. However, in resource-limited settings, access to immunopathological diagnostics is often restricted, posing significant challenges to timely diagnosis and management. We report the case of a 12-year-old girl from rural South-Western Uganda with a history of recurrent vesiculobullous eruptions beginning at 2 years of age, with subsequent episodes at 7 years and a current severe presentation at 12 years. The disease demonstrated a progressive increase in severity with each recurrence. On examination, she had multiple large, tense bullae arranged in annular and polycyclic patterns over the trunk, limbs, thighs, and groin, with a characteristic "string-of-pearls" configuration and no mucosal involvement. Due to unavailability and unaffordability of histopathology and immunofluorescence studies, a clinical diagnosis of LAD of childhood was made based on history, morphology, distribution, recurrence pattern, and exclusion of close differentials. The patient was treated with dapsone, systemic corticosteroids, antibiotic prophylaxis, and local wound care. Within one week of initiating therapy, there was marked clinical improvement, with cessation of new blister formation, resolution of existing bullae, and progressive re-epithelialization. This case underscores the critical role of clinical acumen in diagnosing LAD of childhood in resource-constrained settings where gold-standard investigations are inaccessible. It highlights that a thorough history, careful physical examination, recognition of characteristic lesion patterns, and therapeutic response to dapsone can provide sufficient diagnostic confidence. Importantly, lack of advanced diagnostic tools should not delay initiation of appropriate treatment. This report also emphasizes the need to strengthen diagnostic capacity in low-resource settings while reinforcing the value of clinical judgment in managing rare dermatological conditions.
2026-05-01 | Vancomycin-induced linear IgA bullous dermatosis mimicking Stevens–Johnson syndrome/toxic epidermal necrolysis treated with etanercept
Linear IgA bullous dermatosis (LABD) is a rare subepidermal autoimmune blistering disorder defined by linear IgA deposition at the basement membrane zone of the skin or mucous membranes.1 Drug-induced LABD (DILAD) constitutes a significant proportion of LABD cases, with vancomycin identified as the most common precipitating agent.1,2
2026-05-01 | D104-11 Fatal Linear IgA Bullous Dermatosis Masquerading as Steven-Johnson Syndrome
Abstract Introduction Linear IgA bullous dermatosis (LABD) is a rare autoimmune disorder with generally good prognosis. Here we present for the first time, a case of drug induced LABD, initially thought to be Steven Johnson Syndrome (SJS), which eventually led to necrotizing pneumonia and a fatal outcome. Case A 66-year-old lady with chronic diarrhea due to lymphocytic colitis presented for tachycardia and hypovolemia. She received one dose of ciprofloxacin and metronidazole and was resuscitated with intravenous fluids. The next day, a diffuse petechial rash appeared which developed into bullous lesions within 24 hours. The patient was presumed to have SJS. A skin biopsy was performed, and etanercept was initiated. The biopsy was consistent with LABD, showing inflammatory subepidermal blister with neutrophils, lymphocytes and occasional eosinophils and necrotic keratinocytes with strong linear deposition of IgA present along the basement membrane zone on immunofluorescence, and the patient was started on dapsone and a prednisone taper. During this time, the patient developed new oral and cutaneous lesions due to herpes reactivation [positive for HSV-1 DNA in nasopharynx and in skin lesions]. Her clinical condition worsened secondary to right lower lobe MRSA pneumonia per pulmonary infiltrates and bacteremia. After an initial course of cefepime and linezolid for sepsis and high dose acyclovir for diffuse cutaneous herpes, the antibiotics were narrowed to ceftaroline. Oxygenation initially improved but the patient was persistently bacteremic. Repeat imaging showed cavitary lesions in the right lower lobe. The patient’s condition progressed to shock, ARDS, and was complicated by pneumothorax and acute renal failure. Despite multiple life support treatments, she did not show clinical improvement, and the family transitioned to comfort-oriented care. Discussion LABD is a rare condition affecting 0.2-2.3 cases/million individuals/year, among which fatal complications have rarely been reported. Our patient likely developed LABD due to ciprofloxacin exposure, which is an uncommon association. Her mucosal disruptions likely led to bacterial translocation, and necrotizing pneumonia. Due to her weakened immune status from both LABD and etanercept and prednisone, despite aggressive therapies, she remained persistently bacteremic, which lead to multiorgan failure and to her demise. Our case highlights the importance of prompt evaluation of blistering dermatoses for accurate treatment, and appropriate wound care to prevent infections which can lead to severe complications. This abstract is funded by: None
2026-04-01 | Administration of dupilumab for the treatment of paediatric linear IgA dermatosis inadequately controlled with dapsone and prednisolone
BackgroundOral lichen planus (OLP) is one of the most common non-infectious oral mucosal diseases. Currently, corticosteroid therapy (CST) is regarded as the first-line treatment for OLP, however, long-term use of CST may lead to adverse effects and be ineffective for a minority of patients. Objectives: To systematically evaluate the efficacy of photodynamic therapy (PDT) versus CST in the treatment of OLP.Materials & MethodsA comprehensive search was conducted in Chinese- and English-language electronic databases, including China National Knowledge Infrastructure, Wanfang Data, VIP, PubMed, Embase, and the Cochrane Library, for studies that compared the efficacy of PDT and CST, with the search timeframe set from the establishment of each database to October 2025. Data from eligible studies were analysed using Stata 15.0 software.ResultsIn total,13 randomised controlled trials were included, involving 587 patients (296 in the PDT group and 291 in the CST group). Pooled analysis revealed no statistically significant differences between the two groups in the total effective rate for OLP treatment or in the improvement in Visual Analogue Scale (VAS) score, Thongprasom (TH) sign score, or lesion area (all p>0.05). Subgroup analysis indicated that country and photosensitiser type were the sources of heterogeneity among the studies. Moreover, subgroup analyses revealed that in studies conducted in non-Chinese countries and in studies using phenothiazine dye-based photosensitisers (e.g. toluidine blue), CST showed significantly superior efficacy to PDT in improving VAS score, TH score, and lesion area (p<0.05).ConclusionCurrent evidence indicates that PDT and CST have comparable efficacy in the treatment of OLP. This equivalence positions PDT as a viable non-steroidal alternative, particularly valuable for patients who are intolerant to, have contraindications against, or seek to avoid the local and systemic side effects associated with long-term corticosteroid use.
2026-08-08 | Rituximab for Refractory Adult Linear Iga Bullous Dermatosis: A Case Report
Linear IgA bullous dermatosis (LABD) is a rare autoimmune bullous disease characterized by linear IgA deposition along the basement membrane zone. While dapsone remains the cornerstone of treatment, a subset of adult patients develops severe, treatment-refractory disease requiring prolonged systemic corticosteroid therapy, and the role of rituximab in this setting remains poorly documented. We report the case of a 34-year-old woman with severe mucocutaneous LABD who failed to achieve disease control despite 18 months of treatment with dapsone, high-dose systemic corticosteroids, and doxycycline, resulting in persistent corticosteroid dependence and significant impairment in quality of life. Following confirmation of the diagnosis by repeat histopathology and direct immunofluorescence, rituximab was initiated using the pemphigus protocol (two 1-g infusions administered two weeks apart), followed by maintenance infusions every six months. A marked and sustained clinical improvement became evident from the second treatment cycle, allowing complete withdrawal of systemic corticosteroids and doxycycline, and at the latest follow-up the patient remained clinically stable on dapsone monotherapy, with only minimal residual cutaneous activity. This case highlights rituximab as a promising steroid-sparing rescue therapy for severe refractory adult LABD and contributes to the limited evidence supporting its use in this uncommon autoimmune bullous disease; further studies are needed to establish its optimal treatment regimen and long-term efficacy.
2026-06-16 | Management of Recurrent Linear IgA Dermatosis of Childhood in the Absence of Histopathology and Immunofluorescence: A Case Report from a Low-Resource Setting in South-Western Uganda.
Linear IgA Dermatosis of Childhood (LAD of childhood) is a rare autoimmune sub-epidermal blistering disorder classically confirmed by direct immunofluorescence demonstrating linear IgA deposition along the basement membrane zone. However, in resource-limited settings, access to immunopathological diagnostics is often restricted, posing significant challenges to timely diagnosis and management. We report the case of a 12-year-old girl from rural South-Western Uganda with a history of recurrent vesiculobullous eruptions beginning at 2 years of age, with subsequent episodes at 7 years and a current severe presentation at 12 years. The disease demonstrated a progressive increase in severity with each recurrence. On examination, she had multiple large, tense bullae arranged in annular and polycyclic patterns over the trunk, limbs, thighs, and groin, with a characteristic "string-of-pearls" configuration and no mucosal involvement. Due to unavailability and unaffordability of histopathology and immunofluorescence studies, a clinical diagnosis of LAD of childhood was made based on history, morphology, distribution, recurrence pattern, and exclusion of close differentials. The patient was treated with dapsone, systemic corticosteroids, antibiotic prophylaxis, and local wound care. Within one week of initiating therapy, there was marked clinical improvement, with cessation of new blister formation, resolution of existing bullae, and progressive re-epithelialization. This case underscores the critical role of clinical acumen in diagnosing LAD of childhood in resource-constrained settings where gold-standard investigations are inaccessible. It highlights that a thorough history, careful physical examination, recognition of characteristic lesion patterns, and therapeutic response to dapsone can provide sufficient diagnostic confidence. Importantly, lack of advanced diagnostic tools should not delay initiation of appropriate treatment. This report also emphasizes the need to strengthen diagnostic capacity in low-resource settings while reinforcing the value of clinical judgment in managing rare dermatological conditions.
2026-05-01 | Vancomycin-induced linear IgA bullous dermatosis mimicking Stevens–Johnson syndrome/toxic epidermal necrolysis treated with etanercept
Linear IgA bullous dermatosis (LABD) is a rare subepidermal autoimmune blistering disorder defined by linear IgA deposition at the basement membrane zone of the skin or mucous membranes.1 Drug-induced LABD (DILAD) constitutes a significant proportion of LABD cases, with vancomycin identified as the most common precipitating agent.1,2
2026-05-01 | D104-11 Fatal Linear IgA Bullous Dermatosis Masquerading as Steven-Johnson Syndrome
Abstract Introduction Linear IgA bullous dermatosis (LABD) is a rare autoimmune disorder with generally good prognosis. Here we present for the first time, a case of drug induced LABD, initially thought to be Steven Johnson Syndrome (SJS), which eventually led to necrotizing pneumonia and a fatal outcome. Case A 66-year-old lady with chronic diarrhea due to lymphocytic colitis presented for tachycardia and hypovolemia. She received one dose of ciprofloxacin and metronidazole and was resuscitated with intravenous fluids. The next day, a diffuse petechial rash appeared which developed into bullous lesions within 24 hours. The patient was presumed to have SJS. A skin biopsy was performed, and etanercept was initiated. The biopsy was consistent with LABD, showing inflammatory subepidermal blister with neutrophils, lymphocytes and occasional eosinophils and necrotic keratinocytes with strong linear deposition of IgA present along the basement membrane zone on immunofluorescence, and the patient was started on dapsone and a prednisone taper. During this time, the patient developed new oral and cutaneous lesions due to herpes reactivation [positive for HSV-1 DNA in nasopharynx and in skin lesions]. Her clinical condition worsened secondary to right lower lobe MRSA pneumonia per pulmonary infiltrates and bacteremia. After an initial course of cefepime and linezolid for sepsis and high dose acyclovir for diffuse cutaneous herpes, the antibiotics were narrowed to ceftaroline. Oxygenation initially improved but the patient was persistently bacteremic. Repeat imaging showed cavitary lesions in the right lower lobe. The patient’s condition progressed to shock, ARDS, and was complicated by pneumothorax and acute renal failure. Despite multiple life support treatments, she did not show clinical improvement, and the family transitioned to comfort-oriented care. Discussion LABD is a rare condition affecting 0.2-2.3 cases/million individuals/year, among which fatal complications have rarely been reported. Our patient likely developed LABD due to ciprofloxacin exposure, which is an uncommon association. Her mucosal disruptions likely led to bacterial translocation, and necrotizing pneumonia. Due to her weakened immune status from both LABD and etanercept and prednisone, despite aggressive therapies, she remained persistently bacteremic, which lead to multiorgan failure and to her demise. Our case highlights the importance of prompt evaluation of blistering dermatoses for accurate treatment, and appropriate wound care to prevent infections which can lead to severe complications. This abstract is funded by: None
2026-04-01 | Administration of dupilumab for the treatment of paediatric linear IgA dermatosis inadequately controlled with dapsone and prednisolone
BackgroundOral lichen planus (OLP) is one of the most common non-infectious oral mucosal diseases. Currently, corticosteroid therapy (CST) is regarded as the first-line treatment for OLP, however, long-term use of CST may lead to adverse effects and be ineffective for a minority of patients. Objectives: To systematically evaluate the efficacy of photodynamic therapy (PDT) versus CST in the treatment of OLP.Materials & MethodsA comprehensive search was conducted in Chinese- and English-language electronic databases, including China National Knowledge Infrastructure, Wanfang Data, VIP, PubMed, Embase, and the Cochrane Library, for studies that compared the efficacy of PDT and CST, with the search timeframe set from the establishment of each database to October 2025. Data from eligible studies were analysed using Stata 15.0 software.ResultsIn total,13 randomised controlled trials were included, involving 587 patients (296 in the PDT group and 291 in the CST group). Pooled analysis revealed no statistically significant differences between the two groups in the total effective rate for OLP treatment or in the improvement in Visual Analogue Scale (VAS) score, Thongprasom (TH) sign score, or lesion area (all p>0.05). Subgroup analysis indicated that country and photosensitiser type were the sources of heterogeneity among the studies. Moreover, subgroup analyses revealed that in studies conducted in non-Chinese countries and in studies using phenothiazine dye-based photosensitisers (e.g. toluidine blue), CST showed significantly superior efficacy to PDT in improving VAS score, TH score, and lesion area (p<0.05).ConclusionCurrent evidence indicates that PDT and CST have comparable efficacy in the treatment of OLP. This equivalence positions PDT as a viable non-steroidal alternative, particularly valuable for patients who are intolerant to, have contraindications against, or seek to avoid the local and systemic side effects associated with long-term corticosteroid use.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Linear IgA dermatosis.
1 orphan drug designation for Linear IgA dermatosis.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Human IgG4k monoclonal antibody against CD89 | antibodies | EMA | 2022-10-11 | — | Jjp Biologics Sp. z o.o. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.